Lyell’s LYL314 Gets FDA RMAT Designation for Lymphoma Treatment
Lyell Immunopharma announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to LYL314 for treating relapsed and/or...
Predictive Oncology’s Novel Approach to Abandoned Drugs
Predictive Oncology leveraged its AI-driven drug discovery platform and biobank of live-cell tumor samples to identify new potential uses...
Oryzon Doses First Patient in iadademstat Trial in Small Cell Lung Cancer
Oryzon Genomics has initiated a Phase I/II trial evaluating iadademstat, an LSD1 inhibitor, combined with immune checkpoint inhibitors (atezolizumab...
Icotrokinra Redefines Psoriasis Treatment: Positive Phase 3 Data
Johnson & Johnson’s oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), demonstrated positive Phase 3 results in treating moderate-to-severe plaque psoriasis....
Doxypep Access Marks One Year, STI Rates Halved
MISTR, the largest LGBTQ+ sexual health platform in the U.S., reports a significant 50% drop in STI positivity rates...
BioCardia Starts CardiAMP HF II Patient Enrollment at Emory
BioCardia announced that Emory University School of Medicine is enrolling patients in the Phase III CardiAMP HF II trial,...
Impact Biotech AUA 2025: Padeliporfin VTP Safety and Efficacy Data
ImPact Biotech will present updated preliminary results from its Phase 3 ENLIGHTED study of Padeliporfin VTP in patients with...
Verve Therapeutics Gets FDA Fast Track for PCSK9 Gene Editing Medicine
Verve Therapeutics has received FDA Fast Track designation for VERVE-102, a gene editing medicine designed as a single-course treatment...
Vantage Biosciences Doses First Patient in Phase 2 Study of Oral VX-01 for Diabetic Retinopathy
Vantage Biosciences has initiated a Phase 2 clinical trial of VX-01, an oral therapy for non-proliferative diabetic retinopathy (NPDR)....
Folia Health Launches C3G Study on Rare Renal Disease Impact
Folia Health has launched an at-home study for individuals with C3 glomerulopathy (C3G) in partnership with Novartis. The study...